Conversely, hepatic overexpression of FDXR enhanced mitochondrial oxidative capacity and alleviates steatosis, providing insight into its potential as a therapeutic target for MASLD. Here, FDXR is linked to metabolic dysfunction-associated steatotic liver disease.